Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
about
Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa LRimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human spermThe endocannabinoid system as an emerging target of pharmacotherapyCannabinoid pharmacology: the first 66 yearsEvidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonistThe molecular connections between the cannabinoid system and endometriosisModulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addictionThe role of cannabinoids in adult neurogenesisAM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studiesInternational Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug DevelopmentDecreased reward sensitivity in rats from the Fischer344 strain compared to Wistar rats is paralleled by differences in endocannabinoid signalingBeta-arrestin-based Bret2 screening assay for the "non"-beta-arrestin binding CB1 receptor.Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy.CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling.A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy.Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the FutureActivation of the endocannabinoid system by organophosphorus nerve agents.Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choicePharmacological characterization of cannabinoid receptor activity in the rat-isolated ileum myenteric plexus-longitudinal muscle preparation.Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice.Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys.Permanent suppression of cortical oscillations in mice after adolescent exposure to cannabinoids: receptor mechanisms.Fitting the complexity of GPCRs modulation into simple hypotheses of ligand design.Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.Local pretreatment with the cannabinoid CB1 receptor antagonist AM251 attenuates methamphetamine intra-accumbens self-administration.Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation.Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma.Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticityPolarized cellular patterns of endocannabinoid production and detection shape cannabinoid signaling in neurons(4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs.Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal greyCannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptorThe phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury painEndocannabinoid tone versus constitutive activity of cannabinoid receptors.Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception.
P2860
Q24626361-794A5403-0EBF-467C-981E-D369789358BEQ24634816-A85EBA06-3E4A-4584-8C32-683D051B2AEEQ24648473-53C9C7E7-FB5A-42A2-B44C-9BF85F05259FQ24670395-88FFCF09-9BD9-4EE2-A6EA-8EE1D06D8F9AQ24676188-EF820043-066C-4427-9258-E6ED64F7ED6EQ27005719-21CF09E6-E8FC-45DC-B222-2839A0A9A193Q27014154-3C690E4C-1D34-46FD-8625-54A626D8F486Q28085261-04C34444-5F0C-4CF8-899D-714B5E76365AQ28270589-6E26911C-FFB9-4268-98C1-B3AFB8C302B5Q28298445-89732BB3-4543-4F05-93D1-00B1FC34ED55Q28554883-8A988956-F479-4351-BF10-AB625BAC2AC4Q30470474-F9874F2D-FA7F-4F9D-A8F7-8E59AA003F72Q33436593-CC95FA8F-9080-44DF-9F8F-F35F55E29CB3Q33750632-75C740C8-E02B-44C8-9E90-56BB33D91B12Q33833528-88F55B08-A1CF-45E1-980F-E422DAF6B4A1Q33839407-68CEEB20-50BF-4F32-A6B4-AAB16714EF36Q33980198-172ADAEC-1B0B-4DB0-8B94-E03DD15517C1Q34011342-49C2048D-811D-4BD3-AE6F-FF4F8B01CCDFQ34053352-645B6D65-C908-4391-876A-C4F43F928321Q34078746-E0714C0A-3DAE-4E39-B696-CC17C83E10B3Q34145142-3CF13D76-F190-42B6-B3DF-8B5B1B77A001Q34152254-695B8B00-BED6-4ED3-9F09-28CF8C27247BQ34280424-DBFAAEF8-B526-4984-809B-8E9DACAE8DE7Q34302209-B5B78441-C547-4ABD-AF85-EF5F06005F3BQ34451544-5B677D0A-9245-4108-B9E3-4D42425993CDQ34453695-3F68662B-19FA-4F70-9DAF-310EE6E24853Q34543977-C7C0D432-5144-4794-A4EA-F8924E1DF141Q34545007-03D2B552-91E3-4449-8F3B-2B008C4F5645Q34563164-677CB802-9E32-4321-B74B-ADC09A6641ACQ34574285-71D1F055-057F-4339-AA76-51D59B0F9C8EQ34691684-9F7EB4C2-EBC7-49BA-8F7C-368379EBCA93Q34840647-DF247C89-5A9A-4BEA-A726-28250B53699DQ34946743-6D279CBB-0663-4E64-A9E0-E9ADAE4CDEF1Q34953319-100A25A8-2EBF-4908-9C1F-E2B4B27D8E0FQ34992139-BACA5958-D43E-45AD-8400-CC1367DE65A3Q35048967-32B50E30-EF6D-4153-83B2-791527E53310Q35111468-8E8887CF-BCBC-49F0-89FC-785D456D33D4Q35175618-AC53BE25-1491-41BC-B6AC-5B6A00D01863Q35193265-9E772144-4163-4BF3-94F5-3ED3218F2A97Q35421957-833D9163-907D-43F3-B83F-86E59C52F505
P2860
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
@ast
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
@en
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
@nl
type
label
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
@ast
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
@en
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
@nl
prefLabel
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
@ast
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
@en
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
@nl
P1433
P1476
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
@en
P2093
Roger G Pertwee
P304
P356
10.1016/J.LFS.2004.10.025
P407
P577
2004-12-08T00:00:00Z